Clinical Trials
14 trialsNCT05096663 2026-05-18
Testing the Use of Combination Immunotherapy Treatment (N-803 [ALT-803] Plus Pembrolizumab) Against the Usual Treatment for Advanced Non-small Cell Lung Cancer (A Lung-MAP Treatment Trial)
SWOG Cancer Research Network
Phase 2/3 Active not recruiting
NCT04786964 2025-04-02
CONTERNO
Checkpoint Therapeutics, Inc.
Phase 3 Terminated
NCT02578680 2024-09-20
MK-3475-189
Merck Sharp & Dohme LLC
Phase 3 Completed
NCT03950674 2024-06-10
MK-3475-189
Merck Sharp & Dohme LLC
Phase 3 Completed
NCT04265534 2022-09-21
KEAPSAKE
Calithera Biosciences, Inc
Phase 2 Terminated
NCT00606502 2021-03-05
Study of Pralatrexate vs. Erlotinib for Non-Small Cell Lung Cancer After at Least 1 Prior Platinum-based Treatment
Spectrum Pharmaceuticals, Inc
Phase 2 Completed
NCT00923273 2019-11-26
Sirolimus and Pemetrexed to Treat Non-Small Cell Lung Cancer
National Institutes of Health Clinical Center (CC)
Phase 1/2 Terminated
NCT01165021 2019-09-25
A Study of Pemetrexed/Cisplatin as Pre-operative Treatment of Early Stage Nonsquamous Non-Small Cell Lung Cancer
Eli Lilly and Company
Phase 2 Completed
NCT01999738 2019-02-07
Folic Acid-Tubulysin Conjugate EC1456 In Patients With Advanced Solid Tumors
Endocyte
Phase 1 Completed
NCT00227019 2017-03-06
Phase 2 Trial of Bevacizumab in Combination With Pemetrexed
Stanford University
Phase 2 Completed
NCT00806819 2017-02-02
Lume Lung 2 : BIBF 1120 Plus Pemetrexed Compared to Placebo Plus Pemetrexed in 2nd Line Nonsquamous NSCLC
Boehringer Ingelheim
Phase 3 Completed
NCT01194453 2016-06-16
AP/GP
Sun Yat-sen University
Phase 2 Completed
NCT00033722 2014-01-06
Lometrexol Plus Folic Acid in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer
National Cancer Institute (NCI)
Phase 2 Unknown
NCT00609518 2010-12-28
A Study for Patients With Non-Squamous Non-Small Cell Lung Cancer
Eli Lilly and Company
Phase 2 Completed